利妥昔单抗联合化疗治疗非霍奇金淋巴瘤疗效的Meta分析

摘要

Objective:The study is to provide reference for clinical use and drug policy through systematically evaluating the clinical efficacy of the combined use of rituximab and chemotherapy in the treatment of non -hodgkin′s lymphoma ( NHL).Methods:Literatures of the randomized or clinical controlled trial on the combined use of rituximab and chemotherapy in the treatment of NHL are retrieved in the international and domestic online databases from 1998 to 2014.Results:Meta-analysis showed that the complete remission rate {RR=1.35,95%CI[1.22,1.49]}、3-year overall survival rate {RR=1.30,95%CI[1.03,1.65]} of experimental group and the control group were statistically different, but 5-year overall survival rate {RR=1.45,95%CI[0.83,2.53]} of the experimental group and the control group was not statistically different.Conclusion: Current results indicated that the application of rituximab for the treatment of NHL provided a high level of complete remission rate and 3-year overall survival rate.%目的：系统评价利妥昔单抗联合化疗治疗非霍奇金淋巴瘤（ non-hodgkin′s lymphoma ， NHL）的临床疗效，为临床用药及药物政策提供参考。方法：计算机检索中英文数据库1998～2014年间公开发表的利妥昔单抗联合与单用化疗治疗NHL的随机或临床对照试验（RCT、CCT）文献。结果：治疗组与对照组完全缓解率CR （RR＝1.35，95％CI[1.22，1.49]）、3年总生存率（RR＝1.30，95％CI[1.03，1.65]）有显著性差异；但5年总生存率（RR＝1.45，95％CI[0.83，2.53]）无显著差异。结论：Meta分析结果表明，利妥昔单抗联合化疗治疗NHL比单纯化疗完全缓解率、3年总生存率更高。